Research progress on cardiac allograft vasculopathy / 器官移植
Organ Transplantation
;
(6): 104-2020.
Artículo
en Chino
| WPRIM
| ID: wpr-781863
ABSTRACT
Allogeneic heart transplantation (HTx) is the primary treatment for patients with end-stage heart failure. Nevertheless, the long-term complication of cardiac allograft vasculopathy (CAV) after HTx is the main factor affecting the long-term survival of the recipients. Up to now, there is no effective methods to prevent and treat CAV. This article reviews the pathological manifestations of CAV, immunological factors of CAV and other risk factors of CAV, aiming to provide novel ideas and understanding for CAV research.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Tipo de estudio:
Factores de riesgo
Idioma:
Chino
Revista:
Organ Transplantation
Año:
2020
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS